Astellas/Seagen, Merck Padcev/Keytruda combo shows promise in urothelial cancer in trial

Sep. 12, 2022 9:51 AM ETMerck & Co., Inc. (MRK), SGEN, ALPMY, ALPMFBy: Ravikash, SA News Editor

Modern Medicine Research Laboratory: Diverse Team of Multi-Ethnic Young Scientists Passes Samples in Petri Dish. Advanced Lab with High-Tech Equipment, Microbiology Researchers Design, Develop Drugs

gorodenkoff

Astellas Pharma (OTCPK:ALPMF) (OTCPK:ALPMY), Seagen (NASDAQ:SGEN) and Merck (NYSE:MRK) said Padcev and Keytruda showed a 64.5% confirmed objective response rate (ORR) in patients with a type of urothelial cancer.

The companies presented data from a phase 1b/2 trial, dubbed EV-103 (also known as KEYNOTE-869), Cohort K evaluating Padcev (enfortumab vedotin-ejfv) in combination with Merck's Keytruda (pembrolizumab) and Padcev alone as first-line treatment in patients with unresectable locally advanced or metastatic urothelial cancer (la/mUC) who are ineligible to receive cisplatin-based chemotherapy, at the 2022 European Society for Medical Oncology (ESMO) Congress.

In patients treated with Padcev/Keytruda (n=76) a 64.5% confirmed ORR was seen, the primary goal of Cohort K, with 10.5% of patients experiencing a complete response and 53.9% of patients seeing a partial response, the companies said in a Sept. 12 press release.

Among patients treated with the combo, median progression-free survival (PFS) was not reached, while median overall survival (OS) was 22.3 months.

All-grade treatment-related adverse events (TRAEs) of special interest for the combo were skin reactions (67.1%); peripheral neuropathy — damage to the nerves outside the brain and spinal cord — (60.5%), eye disorders (dry eye, blurred vision, and corneal disorders) (26.3%); hyperglycemia (high blood glucose) (14.5%); and infusion-related reactions (3.9%), the companies added.

Group K also included the monotherapy arm in which patients were treated with Padcev alone (n=73).

Data showed a 45.2% confirmed ORR, with 4.1% of patients experiencing a complete response and 41.1% of patients seeing a partial response, according to the companies.

The median duration of response (DOR) was 13.2 months. Median PFS was 8.0 months and median OS was 21.7 months.

All-grade TRAEs of special interest for Padcev were peripheral neuropathy (54.8%), skin reactions (45.2%), ocular disorders (28.8%), hyperglycemia (11.0%), and infusion-related reactions (5.5%), the companies noted.

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.